Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Non-comparative Double Arm, Open-label, 2-stage, Multicenter Study to Evaluate the Efficacy and Safety of 2 Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer With Maximum TURBT Followed by Induction Platinum-based Chemotherapy/Avelumab Followed by Radiation Therapy Then Maintenance Avelumab or Watch and Wait Approach

NCT06686381 is registered in ClinicalTrials.gov with American University of Beirut Medical Center as lead sponsor.

NCT NCT06686381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06686381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Non-comparative Double Arm, Open-label, 2-stage, Multicenter Study to Evaluate the Efficacy and Safety of 2 Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer With Maximum TURBT Followed by Induction Platinum-based Chemotherapy/Avelumab Followed by Radiation Therapy Then Maintenance Avelumab or Watch and Wait Approach
Lead sponsor
American University of Beirut Medical Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 15, 2025
Completion date
August 15, 2028
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

muscle-invasive bladder cancer